Literature DB >> 11684675

A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation.

Ana Gonzalez-Garcia1, Elia Garrido, Carmen Hernandez, Beatriz Alvarez, Concepcion Jimenez, Doreen A Cantrell, Nicholas Pullen, Ana C Carrera.   

Abstract

The serine/threonine kinase p70 S6 kinase (p70S6K) phosphorylates the 40 S ribosomal protein S6, modulating the translation of an mRNA subset that encodes ribosomal proteins and translation elongation factors. p70S6K is activated in response to mitogenic stimuli and is required for progression through the G(1) phase of the cell cycle and for cell growth. Activation of p70S6K is regulated by phosphorylation of seven different residues distributed throughout the protein, a subset of which depends on the activity of p85/p110 phosphatidylinositol 3-kinase (PI3K); in fact, the phosphorylation status of Thr(229) and Thr(389) is intimately linked to PI3K activity. In the full-length enzyme, however, these sites are also acutely sensitive to the action of FKBP 12-rapamycin-associated protein (FRAP). The mechanism by which PI3K and FRAP cooperate to induce p70S6K activation remains unclear. Here we show that the p85 regulatory subunit of PI3K also controls p70S6K activation by mediating formation of a ternary complex with p70S6K and FRAP. The p85 C-terminal SH2 domain is responsible for p85 coupling to p70S6K and FRAP, because deletion of the C-terminal SH2 domain inhibits complex formation and impairs p70S6K activation by PI3K. Formation of this complex is not required for activation of a FRAP-independent form of p70S6K, however, underscoring the role of p85 in regulating FRAP-dependent p70S6K activation. These studies thus show that, in addition to the contribution of PI3K activity, the p85 regulatory subunit plays a critical role in p70S6K activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684675     DOI: 10.1074/jbc.M103808200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Phosphoinositide 3-kinase controls early and late events in mammalian cell division.

Authors:  Zaira García; Amit Kumar; Miriam Marqués; Isabel Cortés; Ana C Carrera
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

2.  Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

Authors:  Roudy Chiminch Ekyalongo; Toru Mukohara; Yu Kataoka; Yohei Funakoshi; Hideo Tomioka; Naomi Kiyota; Yutaka Fujiwara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2012-07-25       Impact factor: 3.850

3.  The phosphatase subunit tap42 functions independently of target of rapamycin to regulate cell division and survival in Drosophila.

Authors:  Katherine D Cygnar; Xinsheng Gao; Duojia Pan; Thomas P Neufeld
Journal:  Genetics       Date:  2005-03-31       Impact factor: 4.562

4.  Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Authors:  Minghao Sun; Petra Hillmann; Bianca T Hofmann; Jonathan R Hart; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

5.  A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy.

Authors:  Takaaki Senbonmatsu; Takako Saito; Erwin J Landon; Otsu Watanabe; Edward Price; Richard L Roberts; Hans Imboden; Trinita G Fitzgerald; F Andrew Gaffney; Tadashi Inagami
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

6.  STAT3-mediated MLST8 gene expression regulates cap-dependent translation in cancer cells.

Authors:  Hyunji Lee; Hyunjung Chin; Hyeyoung Kim; Hosung Jung; Daekee Lee
Journal:  Mol Oncol       Date:  2020-06-29       Impact factor: 6.603

7.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.